KALA BIO, Inc. has made a significant move by announcing a 1-for-30 reverse stock split of its common shares, effective November 13, 2026. This decision is aimed at enhancing the company's stock price and ensuring compliance with Nasdaq listing requirements. Such corporate actions are common in the pharmaceutical industry, where companies often seek to improve their market perception and attract investors.

According to the recent SEC filing (accession number 0001829126-26-012313), the reverse stock split will automatically combine every thirty shares of issued and outstanding common stock into one share. As a result, the number of shares outstanding will decrease from approximately 19.3 million to about 644,659 shares. This adjustment will not change the par value per share, which remains at $0.001.

Background

KALA BIO, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a company focused on the development of innovative therapies for patients with serious diseases. The company trades on the Nasdaq under the ticker symbol KALA and has been actively engaged in various initiatives to enhance its operational and financial standing.

What the Filing Says

The filing details that the reverse stock split was approved by the company’s stockholders during its annual meeting held on November 3, 2026. The Board of Directors determined the final ratio of the reverse split, which was set at 1-for-30. The filing states, "The Reverse Stock Split will reduce the number of shares of Common Stock outstanding from 19,339,786 shares to approximately 644,659 shares." Additionally, it notes that no fractional shares will be issued; instead, stockholders will receive cash payments for any fractional shares based on the closing price on the Nasdaq on the day of the split.

Impact

This reverse stock split may affect various stakeholders, including existing shareholders who will see their share count reduced but not the overall value of their holdings. It also impacts potential investors who may view the adjusted stock price as more attractive. The company aims to alleviate any concerns regarding its stock price and maintain compliance with Nasdaq's minimum price listing requirement.

What's Next

The common stock will begin trading on a Reverse Stock Split-adjusted basis on the Nasdaq Capital Market on November 16, 2026. The trading symbol for the common stock will remain “KALA.” For more details about the reverse stock split, stakeholders can refer to the definitive proxy statement filed with the SEC on September 24, 2026.